2023
Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review
Majem M, Basch E, Cella D, Garon E, Herbst R, Leighl N. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. Lung Cancer 2023, 187: 107419. PMID: 38070301, DOI: 10.1016/j.lungcan.2023.107419.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage diseaseHealth-related qualityClinical trialsEarly-stage non-small cell lung cancerTreatment-related adverse effectsAppropriate HRQoL instrumentNSCLC clinical trialsCell lung cancerLong-term treatmentLung cancer clinical trialsCancer clinical researchCancer clinical trialsAdjuvant treatmentAdvanced diseaseHRQOL assessmentTreatment landscapeDisease recurrenceHRQoL instrumentsLung cancerDisease progressionLife measuresHRQoLNarrative reviewHealthcare professionals
2006
Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®)
Nakagawa K, Ranson M, Yano S, Tamura T, Saka H, Imamura F, Yokoyama A, Matsui K, Jiang H, Herbst R. Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®). Haigan 2006, 46: 345. DOI: 10.2482/haigan.46.345.Peer-Reviewed Original ResearchProgression-free survivalLong-term treatmentNew safety issuesExtension trialOpen-label extension trialSkin-related adverse eventsMedian overall survivalMajority of patientsLong-term safetyGefitinib monotherapyAdvanced NSCLCAdverse eventsOverall survivalParent trialClinical benefitGefitinib treatmentSafety profileClinical trialsClinical studiesPatientsGefitinibIdeal 1TrialsSafety issuesSurvival